Demondes Haynes, MD
Pulmonary Disease · Jackson, MSNPI 1699716837
Payments from drug & device makers
Across 1,077 payments — averaging $750.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$794K
- Actelion Pharmaceuticals US, Inc.$7K
- Astrazeneca AB$2K
- Amgen$2K
- GSK$991
- AbbVie$488
- plus $2K from 24 others
What the payments were for
- Consulting fees$103,80713%
- Speaking & faculty fees$596,99574%
- Travel & lodging$86,66711%
- Food & beverage$21,2563%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 864 | $794,399 |
| Actelion Pharmaceuticals US, Inc. | 24 | $6,632 |
| Astrazeneca AB | 1 | $2,022 |
| Amgen | 2 | $1,975 |
| GSK | 50 | $991 |
| AbbVie(2 entities) | 26 | $488 |
| Pfizer | 27 | $451 |
| Sanofi | 3 | $224 |
| Insmed, Inc. | 12 | $180 |
| Sunovion Pharmaceuticals Inc. | 8 | $174 |
| Boehringer Ingelheim | 8 | $122 |
| Abiomed | 1 | $120 |
| Bayer | 5 | $103 |
| Inari Medical, Inc. | 4 | $93 |
| United Therapeutics Corporation | 5 | $92 |
| Merck | 5 | $89 |
| Mallinckrodt Enterprises LLC | 4 | $88 |
| Astellas Pharma US Inc | 4 | $85 |
| Pulmonx Corporation | 4 | $72 |
| Genentech USA, Inc. | 4 | $62 |
| Grifols USA, LLC | 3 | $42 |
| Gilead | 2 | $34 |
| Ambu Inc. | 1 | $33 |
| Johnson & Johnson(2 entities) | 2 | $30 |
| Novartis | 2 | $29 |
| Mauna Kea Technologies, Inc. | 1 | $27 |
| La Jolla Pharmaceutical Company | 2 | $26 |
| Philips North America LLC | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Avanos Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$808,736 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 27 | $589,046 |
| OpsumitMacitentan | 43 | $523,116 |
| OfevNintedanib Esylate | 13 | $162,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $35,848 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $23,158 |
| EliquisApixaban | 16 | $13,770 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $11,479 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $9,895 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,423 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 121 | $3,915 |
| Ventolin HfaAlbuterol Sulfate | 24 | $1,970 |
| Tadalafil | 22 | $1,088 |
| Sildenafil Citrate | 13 | $261 |
| Fluticasone Propionate | 46 | $254 |
| Prednisone | 24 | $233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $6,632 | $1,112,16270 claims |
| Boehringer IngelheimOfev | $122 | $162,94513 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $794,399 | $44,53177 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $991 | $40,27146 claims |
| PfizerEliquis | $451 | $13,77016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Jackson
- Michal SenitkoJackson$355K
- Andrew WilhelmJackson$164K
- Maria RappaiJackson$45K
- Raymond PortisJackson$39K
- Kimberly DobbsJackson$35K
- George AbrahamJackson$23K
- Arash SamarghandiJackson$19K
- Richard WellsJackson$19K
- Rajesh PatelJackson$13K
- Charles EvansJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.